Versant Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Versant Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.4K	Buy	465 +296	+175%	+$15.6K	﹤0.01%	1815
2026 Q1	$8.04K	Buy	169 +151	+839%	+$7.96K	﹤0.01%	2223
2025 Q4	$944	Buy	18 +3	+20%	+$180	﹤0.01%	2539
2025 Q3	$972	Hold	15	–	–	﹤0.01%	2513
2025 Q2	$730	Buy	+15	New	+$580	﹤0.01%	2518
2025 Q1	–	Sell	-35	Closed	-$1.38K	–	2541
2024 Q4	$1.38K	Hold	35	–	–	﹤0.01%	2129
2024 Q3	$1.64K	Buy	+35	New	+$1.78K	﹤0.01%	1617
2023 Q3	–	Sell	-42	Closed	-$2.36K	–	1959
2023 Q2	$2.36K	Buy	+42	New	+$2.38K	﹤0.01%	1313

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Versant Capital Management's CRSP Position: Q2 2026 in Review

Versant Capital Management increased its CRISPR Therapeutics (CRSP) stake by 175% in Q2 2026, buying an estimated $15.6K and bringing the position to 465 shares worth $25.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1815.

Versant Capital Management first reported a position in CRSP in Q2 2023 and has held it in 8 quarters since. 63 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Versant Capital Management held 465 shares of CRISPR Therapeutics worth $25.4K as of Q2 2026.
Versant Capital Management bought 296 CRISPR Therapeutics shares in Q2 2026, an estimated $15.6K.
CRISPR Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1815 holding.
Versant Capital Management first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 8 quarters since.
63 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.